Transforma esta função numa entrevista — um currículo e uma carta de apresentação criados à volta do que este empregador procura.
Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring.
Convatec’s revenues in 2025 were over$2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC).
Descrição do cargo
About the role:
The Transformation and Change Manager is responsible for planning, and executing change management initiatives across the organization to successfully deploy a range of tech-based projects. This role focuses on ensuring that process changes are understood and ultimately adopted by our colleagues across the group. They will oversee all aspects of change management, including communication, training development, and execution, while working closely with stakeholders at all levels of the organization to foster a culture of continuous improvement and adaptability.
Convatec provides equal employment opportunities for all current employees and applicants for employment. This policy means that no one will be discriminated against because of race, religion, creed, color, national origin, nationality, citizenship, ancestry, sex, age, marital status, physical or mental disability, affectional or sexual orientation, gender identity, military or veteran status, genetic predisposing characteristics or any other basis prohibited by law.
Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec’s revenues in 2025 were over$2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit: http://www.Convatecgroup.Com.